摘要
慢性肾脏疾病(CKD)是一种进行性疾病,其特点是肾脏功能永久和不可逆转的丧失。根据国际指南,CKD临床诊断方法根据肌酐和白蛋白水平以及肾小球滤过率。不幸的是,这些参数在早期阶段几乎不受影响,其固有的内在可变性只允许确定中间和高级阶段,即预期寿命缩短和治疗构成重大财政投资的阶段。在这方面,若干有针对性的战略aI‘我是为寻找新的标记而设计的。其中,以蛋白质组学和代谢组学研究为基础的“组学”技术应运而生。尿液和血清样本已被选定为起始样本。用于鉴定新的CKD生物标志物,能够区分分期和预测进展结果的材料。在许多情况下,主要目标是快速开发和可靠的无创分析的临床方法,在疾病的早期进展阶段。另一方面,在识别与C相关的分子方面,已经做出了重大的努力。KD的终末期,为了得到充分的治疗,减少损伤,并对生存率有积极的影响。本文介绍了新提出的CKD识别生物标志物的研究现状。综述了其分子多样性,强调了其化学结构差异,并与其生物学相关性进行了比较。在这方面的努力可以提供NCE代谢途径失衡,导致CKD评价和管理的新的整体策略的发展。
关键词: 慢性肾脏疾病(CKD),ESRD,生物标志物,肾小球滤过率,肌酐,代谢组学,蛋白质组学。
Current Medicinal Chemistry
Title:Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Volume: 25 Issue: 31
关键词: 慢性肾脏疾病(CKD),ESRD,生物标志物,肾小球滤过率,肌酐,代谢组学,蛋白质组学。
摘要: Chronic kidney disease (CKD) is a progressive condition characterized by a permanent and irreversible loss of renal function. In accordance to international guidelines, CKD clinical diagnosis methods are based on creatinine and albumin levels and glomerular filtration rate. Unfortunately, these parameters are scarcely affected in early stages, and its inherent intrinsic variability only allows for the identification of intermediate and advanced stages, when life expectancy has become shorter and treatment poses a significant financial investment. In this context, several targeted strategies have been designed for searching novel markers. Among them, "omics" techniques have emerged, mainly based on proteomics and metabolomics research. Urine and serum samples have been selected as starting material to conduct the identification of new CKD biomarkers, capable of differentiating between stages and predicting progression outcomes. In many cases, the principal objective is to develop a fast and reliable clinical method for non-invasive analysis in the early progression stages of the disease. On the other hand, significant efforts have been directed to identify molecules related to the CKD end stage in order to adequate therapies, reduce impairments, and have a positive impact on survival rate. In this article, the state of the art of novel proposed biomarkers for CKD identification is reviewed, with the aim of underlining its molecular diversity, emphasizing chemical structure differences and correlating its biological relevance. Efforts directed in this line could provide evidence of metabolic pathways imbalance, and lead to the development of new integral strategies for CKD evaluation and management.
Export Options
About this article
Cite this article as:
Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis, Current Medicinal Chemistry 2018; 25 (31) . https://dx.doi.org/10.2174/0929867325666180307110908
DOI https://dx.doi.org/10.2174/0929867325666180307110908 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Editorial (A Significant Step Towards New Altitude)
Current Molecular Medicine Thyroid Hormone Ligands and Metabolic Diseases
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Editorial (Hot Topic: Cardiovascular Disease Biomarkers: from Tradition to Modernity)
Current Topics in Medicinal Chemistry Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Exosome and Biomimetic Nanoparticle Therapies for Cardiac Regenerative Medicine
Current Stem Cell Research & Therapy Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Foreword:
Current Pharmaceutical Design Arterial Duct Stenting in Congenital Heart Disease with Duct-Dependent Pulmonary Circulation
Current Pediatric Reviews